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Background: Combining aspirin with warfarin or thienopyridine derivatives (clopidogrel 
and ticlopidine) are increasingly being used in various cardiac conditions. However, little 
is known about the bleeding complications from these combinations at the population 
level. The purpose of this study is to assess the bleeding risk associated with aspirin, 
warfarin and thienopyridine derivatives combinations in the elderly population. 
Methods: We conducted a population-based observational coholt study using a linked 
administrative database. A total of 21,485 elderly (> 65years of age) survivors of acute 
myocardial infarction (AMI) between 1996 and 2000 were studied. Patient’s prescriptions 
were monitored on a monthly basis. Patients were divided into 5 groups according to 
their drug exposures: aspirin, warfarin, aspirin plus a thienopyridine derivative, aspirin 
plus war&in, and aspirin plus warfarin plus a thienopyridine derivative (3-drug combina- 
tion). For bleeding events requiring hospitalization were examined. 
Results: Hospitalizations for bleeding were observed in 1,428 patients. Age > 75 years, 
history of cerebrovascular accident, peptic ulcer disease, diabetes and in-hospital bleed- 
ing during the index AMI were independent predictors for future bleeding (Table). 
Takavuki Kawata, Masao Daimon, Rei Hasegawa, Kiyomi Teramoto, Tomohiko Toyoda, 
Tai Sekine, lssei Komuro, Kyouhei Yamamoto, Daigak” Uchida, Toshiharu Himi, Chiba 
University, Chiba, Japan, Kimitsu Chuo Hospital, Chiba, Japan 
Background: In patients with diabetes mellitus, abnormalities of coronary microcirculation 
distinct from large vessel atherosclerosis have been reported. However, the effects of 
angiotensin-converting enzyme (ACE) inhibition on coronary microcirculation in diabetes 
mellitus is unclear. We aimed to assess whether ACE inhibition improves coronary 
microcirculation in diabetes mellitus, “sing coronary flow reserve (CFR) measurements 
with noninvasive transthoracic Doppler echocardiography (TTDE). 
Methods: We studied 46 patients with type 2 diabetes mellitus (mean age 61& years; 32 
men and 14 women). They were randomly assigned to Temocapril (2mg/day) group or 
Doxazosin (2mgIday) group. All patients underwent treadmill exercise test and positive 
examples were not enrolled. Patients with wall motion abnormality, atrial fibrillation, left 
ventricular hypertrophy were excluded. Coronary flow velocities in the left anterior 
descending artery were recorded with lTDE at rest and during hyperemia induced by 
intravenous infusion of adenosine triphosphate. CFR was calculated as the ratio of hype- 
remit to basal mean diastolic velocity. CFR was assessed before and 4 weeks after 
medication. 
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* Adjustments for predictors of bleeding. 
**Adjusted odds ratio and 95% Cl for 3-drug combination could not be obtained due to 
small sample size. 
Conclusion: At the population level, the combination of aspirin with war&in or thienopy- 
ridines leads to 2 to 3-fold increase in the bleeding risk in the elderly, but the overall risk 
is relatively small. 
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Background: Few trials have examined the efficacy of preventive cardiovascular (CV) 
measures in very elderly patients (275 years old). This report summarizes CV event out- 
comes in this patient subgroup of the Heart Outcomes Prevention Evaluation (HOPE) 
trial. 
Methods: In the randomized. double blind HOPE trial, 6,299 patients ~75 years old and 
996 patients 2775 years old (all with evidence of vascular disease or diabetes plus one 
other CV risk factor) were randomized to receive ramipril (10 @day) or matching pla- 
cebo for a mean of 5 years. The primary outcome was a composite of myocardial infarc- 
tion (MI), stroke, or death from CV causes. Secondary outcomes included stroke, CV 
death, MI, revascularization procedures, congestive heart failure, and overt nephropathy. 
Results: Ramipril has been shown to significantly reduce composite CV events in high- 
risk patients ?55 years of age. In a subgroup analysis of patients 2775 years old, fewer 
patients in the ramipril group experienced primary outcome events (22.9% vs 27.6%, rel- 
ative risk [RR] = 0.61). Although the difference was not statistically significant (95% con- 
fidence interval [Cl], 0.63-l .03). results were consistent with the core HOPE findings. In 
all secondary outcomes, there was a consistent pattern of reduction in CV events in 
patients 275 years old: RR of 0.76 (95% Cl. 0.50-1.15) for stroke; 0.75 (95% Cl, 0.54- 
1.04) for CV death; 0.79 (95% Cl, 0.57-1.10) for MI; 0.96 (95% Cl, 0.71-1.31) for con- 
gestive heart failure; and 0.79 (95% Cl, 0.42-l .50) for overt nephropathy. No significant 
differences were found between the two age groups. Ramipril significantly reduced the 
number of revascularization procedures vs placebo (10.7% vs 17.1%, R&0.60, 95% Cl, 
0.43-0.65) in the very elderly group, who had a greater reduction in risk of revasculariza- 
tion than the younger group (p=O.O314). 
Conclusions: Ramipril offers very elderly patients a reduced risk of revascularization. 
Results in this subgroup show a consistent pattern of risk reduction for primary and sec- 
ondary CV outcomes consistent with the core HOPE findings. 
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Results: CFR data were obtained in 44 (21 temocapril group, 15 doxazosin group, 6 drop 
out) of 46 study patients. There was no significant difference in terms of age, gender, 
body mass index, fasting blood sugar, HbAlc, lipid profile between two groups. In both 
groups, blood pressure was decreased after medication, but there was no significant dif- 
ference between two groups. CFR was increased significantly in the temocapril group but 
CFR in the doxazosin group was similar over each medications. (2.79t0.54 to 3.22kO.74, 
~~0.05, 2.93iO.64 to 3.05iO.59, p=O.79, respectively). 
Conclusion: ACE inhibition improved impaired CFR in type 2 diabetes mellitus. The 
present study suggests, for the first time, that ACE inhibition have a beneficial effects on 
coronary microcirculation in type 2 diabetes mellitus. 
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Background: Beta-blockade improves cardiac function but does not improve exercise tol- 
erance. To determine its effects on skeletal muscle function in heart failure we examined 
regulation of the calcium release channellryanodine receptor (RyRl) that controls skele- 
tal muscle excitation-contraction (EC) coupling and skeletal muscle function in a rat 
model of ischemic heart failure. Methods: Coronary ligation was used to induce ischemic 
heart failure in 24 rats. Half of the rats drank metoprolol-treated drinking water (BB), and 
half drank plain water (HF). A third group (C) of rats did not undergo coronary ligation 
and drank plain water. Hemodynamic data were collected prior to sacrifice at 6 months; 
immediately following sacrifice, soleus muscle contractility and PKA phosphorylation of 
the cardiac and skeletal muscle RyR were determined. Results: There were significant 
differences in LV dP/dt between C (5089 +/- 1605 mm Hgfs, n=5) and both HF (3205 +/- 
1231 mm Hg/s, n=12) and BB (3651 +/- 1034 mm Hg/s, n=12) groups (p=O.O16 and 
0.045. respectively). When HF and BB were compared, there was a significant difference 
in LVEDP (17.4 +/- 8.6 vs. 10.3 +/- 2.9, p=O.O14) and a trend existed (3205 +/- 1231 vs. 
3651 +/- 1034, p=O.O73) between the two groups with regard to LV dP/dt. Skeletal mus- 
cle function demonstrated early fatigue in HF soleus muscle. Both RyRl and RyR2 were 
PKA hyperphosphorylated and relatively depleted of the stabilizing protein, FKBPl2/ 
12.6, consistent with the heart failure serving as a generalized EC coupling myopathy. 
Single channel studies revealed defective channel gating consistent with “leaky” chan- 
nels. Beta-blockade reversed PKA hyperphosphorylation and defective single channel 
function of RyR2 in cardiac muscle. However, the eflects of beta-blockade on skeletal 
muscle were mixed. Half of BB rats demonstrated significant improvement, and the other 
half demonstrated marked deterioration. Conclusion: Beta-blockade normalizes RyR2 
PKA hyperphosphorylation in cardiac and skeletal muscle and improves cardiac function 
yet produces variable results in skeletal muscle function suggesting that other effects of 
beta-blockers are detrimental in heart failure skeletal muscle. 
